Expert Interviews

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.

At ESCRS 2026, Jascha Wendelstein, MD, noted standard ETDRS visual acuity testing misses functional differences between multifocal IOLs that reading-speed testing reveals.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Samantha Harding, MD, discusses how ultra-widefield imaging reduces dilation needs and improves diagnosis in paediatric eye care.

Hove stresses surgeons who prescribe premium lenses or laser surgery to patients should be willing to have those same treatments themselves when needed.

Emami-Naeini previews Retina Society 2026's shift toward AI-derived, quantitative biomarkers in imaging and therapeutics.

Ana Miguel, MD, PhD, explains how artificial intelligence already outperforms experts in glaucoma screening, expands telemedicine access, and reshapes patient conversations.

Giuseppe Giannaccare, MD, PhD, FEBOphth, discusses new data on perioperative low-level light therapy for post-cataract dry eye at ESCRS 2026.

Anat Loewenstein, MD, previews EURETINA 2026 Vienna: the Innovation Spotlight, 17 sessions, symposia, and more.

At ESCRS 2026, Imane Tarib, MD discusses fostering inclusive ophthalmology workplaces and mentorship for early-career surgeons.

OT Roundup debuts with new ADHD ocular findings, a surgeon's own trifocal IOL journey, MOGENRY's FDA filing, and myopia policy news.

ESCRS 2026 data: patient selection and education may be key to aceclidine (VIZZ; LENZ Therapeutics) persistence.

Adam Muzychuk, MD, discusses how AI like the Kane formula is improving outcomes, and why he still urges caution over relying on it for clinical decisions.

Hove explains how his own cataract surgery has changed the way he counsels patients about glare, halos, and near vision.

Jai Parekh, MD, MA, FAAO, says AI is poised to transform eye care—from retinal and glaucoma imaging to cataract surgery—without disrupting it.

Radhika Rampat, MBBS, FRCOphth, discusses how AI is already shaping intraocular lens selection and keratoconus screening, and where anterior segment imaging and patient-facing AI tools are headed next.

At ESCRS 2026, Adam Muzychuk, MD, shares real-world data showing the enVista Envy IOL matches clinical trial outcomes, even in eyes with residual refractive error.

Two-year data presented at ESCRS 2026 show the ELIOS excimer laser procedure sustained IOP reduction and kept most glaucoma patients medication-free.

At ESCRS 2026, Zoltan Z. Nagy, MD, reported that femtosecond laser trabeculotomy (FLigHT) cut intraocular pressure by 27% at 48 months in open-angle glaucoma, with a stable, incision-free safety profile.

A prospective French study found intraoperative OCT most valuable for measuring key surgical distances in deep sclerectomy and MIGS procedures, and useful for training residents.

ESCRS 2026 real-world data: aceclidine (VIZZ; LENZ Therapeutics) drops show fast onset, high satisfaction for presbyopia.

Three-year ESCRS 2026 data show trans-epithelial PRK matches conventional PRK in refractive outcomes, safety, and pain, with faster surgical time.

A real-world study of an enhanced monofocal IOL found most patients achieved 20/20 distance vision and functional intermediate vision without glasses, according to Jai Parekh, MD, MA, FAAO, at ESCRS 2026.

New ESCRS 2026 data show corneal measurements shift meaningfully across the day, with early-morning readings potentially biased by overnight eyelid closure.

At ESCRS 2026 in London, Radhika Rampat, MBBS, FRCOphth, describes bringing low-level light therapy into her refractive practice, from dry eye care to chalazion treatment and pre-surgical ocular surface optimisation.

Suzana Konjevoda, MD, presents data at ESCRS 2026 showing citicoline eye drops aid corneal nerve recovery post-cataract surgery.

Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.